SEC Form 4 · accession 0001209191-19-004447
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Jan 15, 2019
Accepted (ET)
Jan 17, 2019 · 8:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 15, 2019 | M | 103,500 | $10.36 | A | 771,581 | D | |
| Common StockF2 | Jan 15, 2019 | S | 103,500 | $11.713 | D | 668,081 | D | |
| Common Stock | holding | — | — | — | 64,895 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $10.36 | Jan 15, 2019 | M | 103,500 | D | — | Feb 3, 2019 | Common Stock | 103,500 | 0 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018.
- F2This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.36 to $11.97. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3All of the options were fully vested and exercisable as of January 15, 2019.
Remarks
The options exercised were issued to Mr. Crowley in February 2009 and these options would have expired in February 2019.